Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/13/2025

Management of Elevated Alkaline Phosphatase in Adolescents

Initial Assessment and Diagnosis

  • Elevated alkaline phosphatase (ALP) in adolescents is commonly associated with normal bone growth during puberty, but requires evaluation to rule out pathological causes, according to the American Association for the Study of Liver Diseases 1
  • The initial workup for elevated ALP should include a complete biochemical profile, including serum calcium, phosphate, parathyroid hormone (PTH), 25(OH) vitamin D, and creatinine, as recommended by the National Kidney Foundation 2
  • Calculation of tubular maximum reabsorption of phosphate per glomerular filtration rate (TmP/GFR) is essential to assess renal phosphate wasting, as suggested by the National Kidney Foundation 3
  • Assessment for clinical signs of rickets, impaired growth velocity, or bone deformities is crucial in the initial evaluation of elevated ALP, according to the National Kidney Foundation 3

Pathological Causes and Management

  • X-linked hypophosphataemia (XLH) is a pathological cause of elevated ALP, characterized by hypophosphataemia, elevated ALP, and renal phosphate wasting, as described by the National Kidney Foundation 3
  • Other metabolic bone diseases, including rickets and osteomalacia, should be considered as potential causes of elevated ALP, according to the National Kidney Foundation 3, 4
  • Treatment of XLH with oral phosphate supplements and active vitamin D is recommended, with dosage adjustments based on improvement of ALP and PTH levels, as suggested by the National Kidney Foundation 5, 6

Follow-up and Monitoring

  • Regular monitoring of blood levels of ALP, calcium, phosphate, creatinine, PTH, and 25(OH) vitamin D is essential for patients diagnosed with XLH or other pathological causes, as recommended by the National Kidney Foundation 2
  • Assessment of growth parameters, including height, weight, and annual height velocity, is crucial for patients with XLH or other pathological causes, according to the National Kidney Foundation 2
  • Evaluation for bone deformities and musculoskeletal pain is necessary for patients with XLH or other pathological causes, as suggested by the National Kidney Foundation 2